The biopharmaceutical and biotechnology company Symbiotec Pharmalab is set to tap the capital markets with an initial public offering (IPO) worth Rs 1,757 crore. The company has fixed the price band at Rs 938–Rs 988 per share, with the issue opening for subscription on August 24, 2026, and closing on August 27, 2026.
Investors can bid for a minimum of 15 equity shares, with bids thereafter available in multiples of 15 shares. At the upper end of the price band, the minimum investment will be Rs 14,820.
